Full Press Release Details
Disrupting Convention in Women's Health Through Continuous Innovation August 2022 Corporate
Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans
and strategies, results of clinical trials and other future conditions. Words such as, but not limited to, "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will",
"would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements. These forward-looking statements reflect management's beliefs and views with respect to
future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge
from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company qualifies all of the forward-looking statements in
this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Statements
contained herein are made as of the date of this Presentation unless stated otherwise, and neither this Presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is
correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof. Certain information contained in this
Presentation relates to or is based statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as the Company's own estimates.
The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that
their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. The Company's estimates of the patient population with the potential to benefit from
treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and third-party research, which may be based on a small sample size and may fail to accurately
reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions. This Presentation contains trademarks, trade names, or service marks
belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, or by these other parties. 2
Femasys: At-a-Glance Who We Are Financial Information Femasys is a biomedical company aiming to meet
women's needs worldwide with a novel suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health. Headquarters: Suwanee, GA Nasdaq: FEMY IPO date: June 2021 Market Cap:
$28.5M (as of 6/30/22) Cash: $21.8M (as of 3/31/22) 3
Investment Highlights Biomedical Company Disrupting the Approaches to Women's Health with Proprietary
Diagnostic and Device Solutions in Development Addressing Multi-Billion Dollar Global Market Opportunities in Infertility and Permanent Birth Control With Differentiated and Improved Approaches Clear Reimbursement Path with Limited
Competition Yields Improved Patient Care and Health Economics Woman-Founded and Led, Experienced Leadership Team with Concentrated Development Expertise Commercial-Readiness Based on In-House CMC and Device Infrastructure; Audited Systems
Allow for Risk Mitigation Intellectual Property Portfolio with >150 Patents Globally Cash Runway of at Least 12 Months 4
Key Leadership Experienced biotechnology and medical device professionals Kathy
Lee-Sepsick President, CEO, Founder 25+ years of experience Jeffery Marcus, MD Chief Medical Advisor 25+ years of experience Dan Currie Sr. VP, Operations 30+ years of experience Jeremy Sipos VP, Research & Development 20+ years
of experience Lexy Kelley, MD VP, Medical & Clinical Affairs 14+ years of experience Terrell Pruitt VP, Manufacturing 25+ years of experience Edward Evantash, MD Chief Medical Officer 20+ years of experience Mary An Merchant, JD,
PhD VP Counsel, Intellectual Property 25+ years of experience Dov Elefant Chief Financial Officer 25+ years of experience 5
FemVue Contrast-Generating Device FemCath Selective Delivery Catheter FemaSeed Localized
Directional Insemination FemBloc Permanent Birth Control and Ultrasound Occlusion Confirmation FemCerv Endocervical Tissue Sampler FemaSeed FemBloc Product Candidates Localized Directional Insemination Research Preclinical Stage
ISafety Stage IIValidation Stage IIIPivotal DeNovo Clinical Study PMA Clinical Study Our Technologies in Development and Approved are Complimentary TREATMENT TREATMENT Permanent Birth Control and Ultrasound Occlusion
Confirmation FemEMB DIAGNOSTIC Endometrial Tissue Sampler Research Preclinical FemVue Contrast-Generating Device FemCath Selective Delivery Catheter Commercially Available Products FemCerv Endocervical Tissue
Sampler DIAGNOSTIC DIAGNOSTIC DIAGNOSTIC 6
Strong Global Intellectual Property Portfolio Our Patent Estate Encompasses Utility and Design >150
patents globally Directional Delivery (dual or single) to Fallopian Tubes Biopolymer Composition for Tubal Occlusion Contrast Generating Ultrasound Visible Tissue Sampling for Cancer Detection FemBloc, FemaSeed,
FemCath FemBloc FemVue FemCerv FemChec 7
Our Technologies Provide a Continuum of Care In-office, minimally invasive solutions Shared delivery
platforms leverage existing skill sets 8
Femasys Unique In-Office Platform Technologies: Delivery Directed to Fallopian Tubes 9 I. Products
isolate opening of fallopian tube(s) for precise delivery of materials Selective catheter for sperm Dual catheters for biopolymer Selective catheter for contrast Investigational for artificial insemination Investigational for permanent
birth control Commercially Available for fallopian tube assessment (2022) No special skillset and no capital equipment No cannulation of tube Patents issued and pending No anesthesia and no incisions
Femasys Unique In-Office Platform Technologies:Diagnostic Contrast for Ultrasound 10 II. Products
generate natural contrast for ultrasound evaluation of fallopian tubes Assess patency for infertility diagnosis Assess occlusion post FemBloc Commercially Available Investigational Safe and affordable No radiation or x-ray contrast
dye No referral and saves time Patents issued and pending
Femasys Unique In-Office Platform Technologies:Tissue Sampling for Cancer Diagnosis 11 III. Products
collect and contain comprehensive sample to maximize quality & quantity Endocervical curettage Endometrial biopsy Commercially Available for cervix assessment (2022) R & D for uterine cavity assessment Coming Soon Safe and
reliable 360 tissue capture Virtually pain free Patents issued
12 FemaSeed Localized Artificial Insemination Developing the first and only first-line approach
designed to deliver sperm where conception occurs Designed to be more affordable than assisted reproduction Companion Diagnostics FemVue and FemCath Includes first in-office ultrasound diagnosis of fallopian tubes for
infertility Infertility Focused Portfolio
Infertility: Unmet Need (U.S. only) >10M struggle with infertility Despite advancements, there
have been no new affordable options in decades. 13 https://www.cdc.gov/nchs/nsfg/key_statistics/i-keystat.htm
FemaSeed: Low Cost for the Front End of Infertility Treatment FemaSeed $$ Traditional
IUI $ IVF $$$$$ Artificial Insemination Directed sperm delivery (into fallopian tube where conception occurs) No ovulation stimulation optional optional No embryo transfer Minimal training 14
FemaSeed Localized Directional Insemination in Development There's been limited advancements and
continuous demand for less costly options Undirected sperm delivery to cavity (IUI) is first-line treatment despite low success rates First and only approach delivering sperm where conception occurs 15
Summary: Study Design: multi-center, unblinded, prospective study # Subjects: 792 subject cycles
Primary Effectiveness Endpoint: pregnancy rate by 7 weeks post procedure Interim Analysis Planned Summary: Study Design: multi-center (7 U.S. sites), prospective post-market study # Subjects: 23 (45 tubes) Study Objective: observation
of saline-air contrast to assess selective tubal infusion Results: 89% (40/45) had contrast enter tube combined with sustained flow or exit into peritoneal cavity No serious safety events reported Evaluated Delivery
Effectiveness FemaSeed de Novo Clinical Trial for Grant/ Clearance SITE RECRUITMENT UNDERWAY Early Clinical (completed) Pivotal Trial: Safety & Effectiveness(IDE Approved April 2021) 16 1st Subject Treated July 2021 INTERIM DATE
The Unmet Need for Women: Options for Infertility 17 For more than 20 years, current approaches
to infertility treatment have been limited during the initial stage of therapeutic care, but with the advancement of FemaSeed, we believe a next generation intrauterine procedure may have the opportunity to truly change this traditional
paradigm. Michael Glassner, MD Founding Partner and Medical Director of Main Line Fertility & Reproductive Medicine
The Unmet Need for Women: Options for Infertility 17 For more than 20 years, current approaches to
infertility treatment has been limited during the initial stage of therapeutic care, but with the advancement of FemaSeed, we believe a next generation intrauterine procedure may have the opportunity to truly change this traditional
paradigm. Michael Glassner, MD Founding Partner and Medical Director of Main Line Fertility & Reproductive Medicine
Companion Products: Diagnostic Test Prior to Infertility Treatment, including FemaSeed Diagnostic
performed prior to any infertility procedures Can be combined with uterine cavity evaluation (standard of care) On-line training and support available for new customers Physician locator available on patient website Reimbursed using
existing codes First In-office, Ultrasound Approach for Fallopian Tube Evaluation Commercially Available: U.S., Japan, and other When paired with FemCath allows for selective tubal evaluation FemVue creates saline-air contrast that
travels through the fallopian tube(s) when open 18
Companion Products: Diagnostic Test Prior to Infertility Treatment, including FemaSeed Diagnostic
performed prior to any infertility procedures Can be combined with uterine cavity evaluation (standard of care) On-line training and support available for new customers Physician locator available on patient website Reimbursed using
existing codes First In-office, Ultrasound Approach for Fallopian Tube Evaluation Commercially Available: U.S., Europe, Canada, Japan, other When paired with FemCath allows for selective tubal evaluation FemVue creates saline-air contrast
that travels through the fallopian tube(s) when open 18
FemVue: Compelling Patient Testimonials 19 Being aware that there are many reasons why women have
issues conceiving, FemVue is one easy procedure that can assist in finding out why it may have been difficult. As such, I highly recommend any woman who has tried for months or years to conceive to get the FemVue procedure. It is a procedure
that will get you immediate results for you and your doctor to discuss the next steps of making your dreams come true. After a month of completing successful medical procedures including FemVue, my husband and I conceived our first child.
Fertility Enabling Market Opportunity (U.S.) Near-Term Target Market $800M Total Market Expansion
Opportunity $2B Total Includes women choosing IUI and required tubal diagnosis Intrauterine Insemination (IUI) Diagnosis / Drugs Discussion Only IVF (~200k cycles/ year)* >10M Infertile Women Most Expensive Least
Expensive 20 *Centers for Disease Control and Prevention. 2019 Assisted Reproductive Technology Fertility Clinic and National Summary Report. US Dept of Health and Human Services; 2021.
FemBloc Permanent Birth Control First and only non-surgical, in-office, permanent birth control option
in development with the potential to be the safest and most natural approach at half the cost of the long-standing surgical alternative 21 Contraception Focused Portfolio Companion Diagnostics FemChec and FemCath Includes first in-office
ultrasound diagnosis of fallopian tubes for confirmation of procedure success
Since surgical tubal ligation has been performed since the 1880's and remains the most common option for
women who want permanent birth control. Permanent Birth Control Alternatives: Unmet Need (U.S. only) >13M women no longer intend to have children >12M use non-permanent birth control, long-term 800,000 women choose surgical tubal
ligation as a form of permanent birth control every year* More than 100 years of stagnant innovation for permanent birth control 22 *Frattarelli 2007
*6% failure rate for laparoscopic sterilization (tubal ligation) and 5% failure rate for hysteroscopic
sterilization (Essure), reported in published study as higher than expected (Fertility and Sterility, 2022) Essure is a registered trademark of Bayer Healthcare (Conceptus) and, as of December 2018, no longer a marketed solution. FemBloc:
Expected Competitive Advantages Over Existing or Previous Birth Control Options On-Market Solutions Off-Market FemBloc Surgical Tubal Ligation* IUD (Reversible) Essure * Permanent Office Procedure Some No Special
Capital Equipment No Anesthesia No Coil Implant/ Clip No Hormones One-Time Treatment Cost Multiple IUDs Worldwide Applicability Varies 23
Companion ultrasound procedure exclusive to FemBloc - confirms procedure success Occlusion
Confirmation No Permanent Implant - Scar Tissue Closes Tubal Lumen FemBloc Treatment FemBloc Permanent Birth Control in Development The first and only non-surgical, in-office approach Balloon at tubal opening without
cannulation Biopolymer is designed to be expelled within 3 months 3 Months Blockage Biopolymer solidifies Biopolymer degrades Saline-air contrast confirms blockage 24
Summary: n=183 subjects being followed for 5 years Patients found procedures highly tolerable 96%
physicians assessed procedure to be extremely/ very simple 99% physicians assessed easier than tubal ligation surgery Summary: n=93 subjects received planned hysterectomy Subset with histopathology demonstrating biopolymer tissue
reactions No serious safety events reported Goals: n=50 subjects receive two confirmation tests to allow selection of ultrasound or radiology test Evaluate adequacy of improvements to procedures, products and training Goals: IDE approval
of study design(multi-center, unblinded prospective study); First-mover advantage utilizing previous FDA approved third-party study designs: primary endpoint of pregnancy rate at 1 year post confirmation test safety follow-up 2-5 years
post-market Safety & Effectivenessof FemBloc Selection of ConfirmationTest for Pivotal No Serious AEs Reported Evaluated Delivery &Biopolymer Effectiveness FemBloc Clinical Studies for Pre-Market Approval (PMA) SITE RECRUITMENT
UNDERWAY Early Clinical Stage I: Safety Stage II: Validation (on-going) Stage III: Pivotal (pending) 25 ENROLLMENT COMPLETION EXPECTED Q3 2022 FILE IDE EXPECTED Q1 2023
165 27 53 8 2 2 3 5 12 1 FemBloc Treatment (90 days) FemBloc: Majority AEs Were Mild